Recombinant Antibodies: Enhance Your Research with Quality Solutions

Discover the cutting-edge technology in antibody research with our innovative recombinant antibodies from Alpha Lifetech Incorporation. Our recombinant antibodies are engineered for high specificity and affinity, offering superior performance in various applications such as Protein detection, immunoprecipitation, and flow cytometry, With our state-of-the-art production facilities and expertise in antibody engineering, we are dedicated to delivering reliable and consistent recombinant antibodies to meet the diverse needs of our customers in research, diagnostics, and therapeutic development. Our recombinant antibodies exhibit reduced batch-to-batch variation and enhanced stability, providing researchers with confidence in their experimental results, At Alpha Lifetech Incorporation, we are committed to advancing the field of antibody technology and empowering scientists with high-quality tools for their research. Whether you are studying protein-protein interactions, investigating disease mechanisms, or developing novel therapeutic targets, our recombinant antibodies are designed to support your research goals and propel scientific discovery, Experience the power of recombinant antibodies with Alpha Lifetech Incorporation and elevate your research to new heights

Hot Selling Product

ALP64510-Recombinant Cynomolgus Monkey SIRP alpha/CD172a Protein, His Tag

ALP64517-Recombinant Human CD223/LAG3 Protein, His Tag, Avi Tag

ALP64524-Recombinant Human TNFRSF17/BCMA Protein, Fc Tag, Avi Tag

ALP64560-Recombinant Human CD28 Protein, mFc Tag

ALP64505-Recombinant Human CD24 Protein, mFc Tag

ALP64567-Recombinant Rabbit CD86 Protein, His Tag

Excellence in Recombinant Antibodies Global Reach Service

At Alpha Lifetech Inc., we recognize that the demand for advanced biotechnological solutions is global, and we are committed to providing excellence in recombinant antibodies through our comprehensive services. Founded by a dedicated team of scientists with deep expertise in membrane protein production, Nanobody discovery, and monoclonal development, we leverage our technical know-how to supply nearly 10,000 high-quality reagents, cytokines, and drug target antibodies tailored to meet the needs of researchers and companies worldwide. Our global outreach underscores our mission to deliver cutting-edge products and services with unmatched reliability. With an extensive catalog that encompasses various applications in drug discovery and development, we enable our clients to enhance their research outcomes. By fostering partnerships and constantly innovating, Alpha Lifetech Inc. ensures that procurement is seamless and efficient for our international clients, allowing them to focus on advancing their scientific endeavors while we handle the complexities of antibody sourcing. In a landscape where precision and quality are paramount, our recombinant antibodies stand out for their specificity and efficacy. As we expand our reach and continuously refine our offerings, we invite global buyers to explore our solutions and experience the Alpha Lifetech commitment to excellence firsthand. Partner with us and discover how we can support your research initiatives with the highest standards in biotechnological products.

Excellence in Recombinant Antibodies Global Reach Service

Service Type	Description	Region	Lead Time (Weeks)	Price (USD)
Custom Antibody Production	Full-service production of monoclonal and polyclonal antibodies tailored to specific needs.	North America	12	$5,000
Recombinant Antibody Engineering	Engineering and optimization of recombinant antibodies for enhanced properties.	Europe	16	$8,500
Antibody Characterization	Comprehensive profiling including specificity, affinity, and functional assays.	Asia	8	$4,000
Antibody Production Scale-up	Scaling up production processes for clinical applications.	Australia	24	$15,000
Monoclonal Antibody Development	Development services for monoclonal antibodies from project initiation to validation.	Global	20	$12,000

Global Trends in Recombinant Antibody Development (2018-2023)

The chart above illustrates the significant growth in recombinant antibody applications from 2018 to 2023. The data shows a steady increase in the use of recombinant antibodies, starting from 150 applications in 2018 and reaching an impressive 800 applications by 2023. This exponential growth can be attributed to the rising demand for targeted therapies in various medical fields, including oncology, immunology, and infectious diseases. Innovations in biotechnology and advancements in research and development have also played a critical role. As the global healthcare landscape continues to evolve, recombinant antibodies are poised to become increasingly integral in therapeutic interventions, ensuring a robust market presence in the upcoming years. The trend highlights the importance of continued investment and innovation in biopharmaceutical research to meet the growing demand for efficient and effective healthcare solutions.